title: Clinical potential of the ERG oncoprotein in prostate cancer.
abstract: Oncogenic activation of ERG resulting from gene fusion is present in over half of all patients with prostate cancer in Western countries. Although the underlying genetic mechanisms have been extensively studied, evaluation of the ERG oncoprotein--the translational product of ERG gene fusions--has just begun. The robust correlation between ERG oncoprotein detection and gene fusion status enables rapid characterization of this protein in large patient cohorts. Recent studies have focused on characterizing the ERG oncoprotein and determining its potential role in the diagnosis and biological stratification of prostate cancer.
authors.affiliation: Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, 1530 East Jefferson Street, Rockville, MD 20852, USA.
authors.forename: Philip
authors.initials: P
authors.lastname: Rosen
authors.forename: Isabell A
authors.initials: IA
authors.lastname: Sesterhenn
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Brassell
authors.forename: David G
authors.initials: DG
authors.lastname: McLeod
authors.forename: Shiv
authors.initials: S
authors.lastname: Srivastava
authors.forename: Albert
authors.initials: A
authors.lastname: Dobi
mesh_terms: D000818:Animals; D014408:Biomarkers, Tumor / Q000096:biosynthesis*; D015331:Cohort Studies; D006801:Humans; D008297:Male; D015513:Oncogene Proteins / Q000096:biosynthesis*; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000378:metabolism*; D015534:Trans-Activators / Q000096:biosynthesis*; D000071230:Transcriptional Regulator ERG
chemical_list: D014408:Biomarkers, Tumor; C072312:ERG protein, human; D015513:Oncogene Proteins; D015534:Trans-Activators; D000071230:Transcriptional Regulator ERG